In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.
BACKGROUND Despite advances in the development of medications to treat alcohol dependence , few medications have been approved by the U.S. Food and Drug Administration . The use of certain anticonvulsant medications has demonstrated potential efficacy in treating alcohol dependence . Previous research suggests that the anticonvulsant levetiracetam may be beneficial in an alcohol-dependent population of very heavy drinkers . METHODS In this double-blind , r and omized , placebo-controlled clinical trial , 130 alcohol-dependent patients who reported very heavy drinking were recruited across 5 clinical sites . Patients received either levetiracetam extended-release ( XR ) or placebo and a Brief Behavioral Compliance Enhancement Treatment intervention . Levetiracetam XR was titrated during the first 4 weeks to 2,000 mg/d . This target dose was maintained during weeks 5 through 14 and was tapered during weeks 15 and 16 . RESULTS No significant differences were detected between the levetiracetam XR and placebo groups in either the primary outcomes ( percent heavy drinking days and percent subjects with no heavy drinking days ) or in other secondary drinking outcomes . Treatment groups did not differ on a number of nondrinking outcomes , including depression , anxiety , mood , and quality of life . The only difference observed was in alcohol-related consequences . The levetiracetam XR treatment group showed significantly fewer consequences than did the placebo group during the maintenance period ( p = 0.02 ) . Levetiracetam XR was well tolerated , with fatigue being the only significantly elevated adverse event , compared with placebo ( 53 % vs. 24 % , respectively ; p = 0.001 ) . CONCLUSIONS This multisite clinical trial showed no efficacy for levetiracetam XR compared with placebo in reducing alcohol consumption in heavy drinking alcohol-dependent patients
In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .